A Phase 1, Randomized, Subject- And Investigator-Blind, Sponsor Open, Placebo Controlled, Single Ascending Dose Escalation Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04958242 Following Oral Dose Capsules In Healthy Subjects

Trial Profile

A Phase 1, Randomized, Subject- And Investigator-Blind, Sponsor Open, Placebo Controlled, Single Ascending Dose Escalation Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04958242 Following Oral Dose Capsules In Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Dec 2015

At a glance

  • Drugs PF 4958242 (Primary)
  • Indications Schizophrenia; Sensorineural hearing loss
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 16 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 23 Oct 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top